期刊文献+

34βE12、CK19与TPO在甲状腺乳头状癌与甲状腺乳头状增生鉴别诊断中的价值 被引量:4

下载PDF
导出
摘要 目的探讨34βE12、CK19及TPO在甲状腺乳头状癌与甲状腺良性乳头状增生鉴别诊断中的应用价值。方法用免疫组化EnVision法检测甲状腺乳头状癌及乳头状增生各50例的34βE12、CK19及TPO抗体表达情况。结果 50例甲状腺乳头状癌的34βE12、CKl9及TPO的阳性表达率分别为92.0%、100.0%及8.0%;50例良性乳头状增生的34βEl2、CKl9和TPO的阳性表达率分别为0.09%、22.0%及100.0%,两组阳性率比较具有显著性差异(均P<0.05)。结论 34βE12、CK19及TPO对甲状腺乳头状癌和乳头状增生有鉴别价值,联合测定效果更好。
出处 《浙江实用医学》 2012年第2期88-89,F0003,共3页 Zhejiang Practical Medicine
  • 相关文献

参考文献6

二级参考文献29

  • 1杨清绪,邵春奎,冯智英,黄本强,韩安家,熊敏,赵文丽,武彤彤.CK19和甲状腺过氧化物酶表达在甲状腺疾病诊断中的作用[J].第一军医大学学报,2005,25(6):678-681. 被引量:12
  • 2张静,李雯,梁颜笑,陈金培.甲状腺增生性病变中CK19、TPO、Galectin-3的表达及在病理诊断中的应用[J].广州医学院学报,2005,33(2):8-12. 被引量:4
  • 3王晓红,刘雨飞,鲍宇浓,崔全才,王德田.甲状腺乳头状癌RET、CK19、TG、Ki-67的表达[J].临床与实验病理学杂志,2006,22(6):692-695. 被引量:14
  • 4方海飞,沈美萍,徐银峰.甲状腺乳头状癌TGF-β_1、CD_(31)表达与肿瘤转移的关系[J].南京医科大学学报(自然科学版),2007,27(5):472-475. 被引量:16
  • 5中山医科大学 同济医科大学.外科病理学,第2版[M].武汉:湖北科学技术出版社,1998.1299-304.
  • 6Liberman E, Weidner N. Papillary and follicular neoplasms of the thyroid gland. Differental immunohistochemical staining with high-molecular-weight keratin and involucrin. Appl Immunohistochem Mol Morphol, 2000; 8 ( 1 ) : 42.
  • 7Raphael SJ, McKeown-Eyssen G, Asa SL. High-molecular-weight cytokeratin and cytokeratin-19 in Me diagnosis of thyroid tumors. Mod Pathol, 1994; 7(3):295.
  • 8Henzen Logmans SC, Mullink H, Ramaekers FC, et al.Expression of cytokeratins and vimentin in epithelial cells of normal and pathologic thyroid tissue. Virchows Arch A Pathol Anat Histopathol, 1987; 410(4):347.
  • 9Vialc G, Dell Orto P, Coggi G,et al. Co-expression of cytokeratins and vimentin in normal and discased thyroid glands : lack of diagnostic utility of vimentin immunostaiing.Am J Surg Pathol, 1989; 13(12):1034.
  • 10Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol, 2001; 14(4) :338.

共引文献43

同被引文献32

  • 1徐其银.Galectin-3和Cytokeratin-19在桥本甲状腺炎并发微小乳头状癌中不同区域的表达[D].昆明医学院.2010
  • 2Xu XC,NI Naggar AK,Lotan R,et al.Differential expression of galectin-1 and galectin-3 in thyoid tumors: potential diagnostic implications[].American Journal of Pathology.1995
  • 3Saleh HA,Jin B,Barnwell J,et al.Utility of immunohistochemical markers in differentiating benign from malignant follicular-de-rived thyroid nodules[].Diagnostic Pathology.2010
  • 4Rosenbaum MA,McHenry CR.Contemporary management of papillary carcinoma of the thyroid gland[].Expert Review of Anticancer Therapy.2009
  • 5Htwe TT,Karim N,Wong J,et al.Differential expression of galectin-3 in advancing thyroid cancer cells:a clue toward understanding tumour progression and metastasis[].Singapore Medical Journal.2010
  • 6Di Cristofaro J,Silvy M,Lanteaume A,et al.Expression of TPO mRNA inthyroid tumors:quantitative PCR analysis and correlation with alter-ations of ret,Braf,ras and pax8genes[].Endocrine Related Cancer.2006
  • 7Delellis RA,Lloyd RV,Heitz PU,et al.Tumours of Endocrine Organs[].Word Health Organization Classification of TumoursPathology&Genetics.2004
  • 8Park YJ,Kwak SH,Kim DC,et al.Diagnotic value of Galectin-3,HBME-1,cytokeratin19,high molecular weight cytokeratin,cyclin D1and p27in the differential diagnosis of tyroid nodules[].Journal of Korean Medical Science.2007
  • 9Bose D,Das RN,Chatterjee U,et al.Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma[].Indian J Med Pae diatr Oncol.2012
  • 10Savin S,Cvejic D,Isic T,et al.Thyroid peroxidase and Galectin-3 im-munostaining in differentiated thyroid carcinoma with clinicopath olog-ic correlation[].Human Pathology.2008

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部